Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: A phase II study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 2, 2000, Pages 132-139

  Ferraresi, Virginia ^a   Milella, Michele ^a   Vaccaro, Angela ^a   D'Ottavio, Anna Maria ^a   Papaldo, Paola ^a   Nisticò, Cecilia ^a   Thorel, Maria Francesca ^a   Marsella, Annelisa ^a   Carpino, Armando ^a   Giannarelli, Diana ^a   Terzoli, Edmondo ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anthracycline, pretreated; Docetaxel; G CSF; Metastatic breast cancer; Paclitaxel, pretreated; Premedication; Toxicity

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; ONDANSETRON; PREDNISONE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; FLUID RETENTION; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PROPHYLAXIS; STOMATITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; COHORT STUDIES; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUCOCORTICOIDS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; PREDNISONE; TAXOIDS;

EID: 0033638024     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200004000-00006     Document Type: Article

References (25)

1. Cancer in the European community and its member states
2. Survival from first recurrences: Relative importance of prognostic factors in 1,015 breast cancer patients
3. Malignant tumors of the breast
4. Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol
5. Reversal of resistance to Taxol and Taxotere by dexniguldipine-HCl: Dose dependent modulation in various human MDR cell lines
6. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue
7. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer
8. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer
9. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer
10. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Cooperative Group of the EORTC
11. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Cooperative Group of the EORTC
12. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer
13. Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group
14. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
15. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
16. The taxoids: Same roots, different drugs
17. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer
18. Response to dexamethasone in patients with fluid retention after docetaxel
19. Comprehensive criteria for assessing therapy-induced toxicity
20. Reporting results of cancer treatment
21. Nonparametric estimation from incomplete observation
22. Docetaxel as single-agent therapy in metastatic breast cancer: Clinical efficacy
23. Anthracycline resistance: The problem and its current definition
24. A unified definition of clinical anthracycline resistant breast cancer (ARBC)
25. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer